The cost of the medication may pose a financial burden on patients and healthcare systems, particularly for those without comprehensive insurance coverage
Weeks 36 Appetite suppression becomes more noticeable, and gradual weight reduction begins
Retatrutide is not approved by Health Canada, the FDA, or any regulatory authority for any indication as of December 2025
The prespecified primary outcome was the difference in mean percentage body weight change between patients randomized to semaglutide versus placebo at 68 weeks
Scientific Overview: DSIP (Delta Sleep-Inducing Peptide, Emideltide) is a synthetic nonapeptide extensively studied for its unique regulatory properties related to sleep induction and neuroendocrine functions
It calms overactive immune responses at the mucosal level, supporting gut barrier repair and reducing the inflammatory signaling that drives skin and digestive symptoms